Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q3 FY2023 Earnings Presentation
23 slides from Jubilant Pharmova's earnings presentation, Feb 3, 2023
Slide 1: Financial Results Quarter Ended December 31, 2022
Financial Results Quarter Ended December 31, 2022
Slide 2: Conference Call Details
Conference Call Details Date : Feb 03, 2023 Time : 04:00 pm IST +91 22 6280 1141 Primary Number +91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay: Feb 03 to Feb 10, 2023 Dial-in: +91 22 7194 5757 / +91 22 6663 5757 Playback
Slide 3: Chairmen’s Message
Chairmen’s Message Commenting on Company’s Q3’FY23 performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “During the quarter, Company reported higher revenues YoY led by increase in sales in Radiopharmacies, Allergy and CD
Slide 4: Q3'FY23 Results Analysis
Q3'FY23 Results Analysis 3
Slide 5: Financial Highlights – Q3'FY23
Financial Highlights – Q3'FY23 Particulars1 Q3'FY22 Q2'FY23 Q3'FY23 Revenues were at Rs 1,553 Crore vs. Rs 1,311 Crore in Q3'FY22 and Rs Total Revenue from Operations 1,311 1,600 1,553 1,600 Crore in Q2’FY23 Reported EBITDA 200 232 155 Depreciation and Amortisation 93 94 94 Reported EBITDA was a
Slide 6: Specialty Pharmaceuticals Segment Highlights – Q3'FY23
Specialty Pharmaceuticals Segment Highlights – Q3'FY23 Particulars1 Q3'FY22 Q2'FY23 Q3'FY23 YoY (%) Revenues were at Rs 760 Crore vs. Rs 635 Crore in Q3'FY22 and Total Revenue 635 814 760 20% Rs 814 Crore in Q2’FY23 a) Radiopharma 510 658 613 20% i) Radiopharmaceuticals 197 248 213 8% EBITDA was
Slide 7: CDMO Sterile Injectables Segment Highlights – Q3'FY23
CDMO Sterile Injectables Segment Highlights – Q3'FY23 Particulars1 Q3'FY22 Q2'FY23 Q3'FY23 YoY (%) CDMO Sterile Injectables’ revenues were at Rs 272 Crore vs. Rs 265 Revenue 265 299 272 3% Crore in Q3'FY22 and Rs 299 Crore in Q2’FY23 EBITDA 116 71 56 (52%) Reported EBITDA Margin (%) 44.0% 23.8% 20
Slide 8: Generics Segment Highlights – Q3'FY23
Generics Segment Highlights – Q3'FY23 Particulars1 Q3'FY22 Q2'FY23 Q3'FY23 YoY (%) Q3’FY23 performance improvement was on account of higher production Revenue 171 161 223 30% at Roorkee plant and sales in non-US markets. This was partially offset by Reported EBITDA (43) (82) (36) shutdown at Salis
Slide 9: CRDMO Segment Highlights – Q3'FY23
CRDMO Segment Highlights – Q3'FY23 Particulars1 Q3'FY22 Q2'FY23 Q3'FY23 YoY (%) • Revenues were at Rs 291 Crore vs. Rs 236 Crore in Q3'FY22 and Rs 320 Total Revenue 236 320 291 23% Crore in Q2’FY23 a) Drug Discovery Services 120 150 123 3% b) CDMO - API 116 170 168 45% • EBITDA was at Rs 39 Crore vs
Slide 10: Jubilant Therapeutics: A precision oral therapeutic company focused on oncology
Jubilant Therapeutics: A precision oral therapeutic company focused on oncology JBI-802: coREST inhibitor/Dual epigenetic modulator for synergistic anti-tumor activity Differentiated JBI-778: brain penetrant PRMT5i with differentiated safety, focused on synthetic lethality to specific Pipeline mutat
Slide 11: Jubilant Therapeutics: Broad Pipeline of Differentiated Assets with Improved Therapeutic Index
Jubilant Therapeutics: Broad Pipeline of Differentiated Assets with Improved Therapeutic Index Program Mechanism Indications Lead Optimization Pre-Clinical (IND) Phase I/II Milestones coREST Inhibitor/ ET/MPN and neuro JBI-802 Epigenetic Phase I/II studies ongoing endocrine tumors Modulating Agent P
Slide 12: 9M'FY23 Results Analysis
9M'FY23 Results Analysis
Slide 13: 9M'FY23 Financial Highlights
9M'FY23 Financial Highlights Particulars1 9M'FY22 9M'FY23 Revenues were Rs 4,604 Crore versus Rs 4,603 Crore in 9M'FY22. Total Revenue from Operations 4,603 4,604 Reported EBITDA at Rs 591 Crore vs. Rs 923 Crore in 9M'FY22. Reported EBITDA 923 591 Depreciation and Amortisation 281 283 In 9M’FY
Slide 14: Specialty Pharmaceuticals Segment Highlights – 9M'FY23
Specialty Pharmaceuticals Segment Highlights – 9M'FY23 Particulars1 9M'FY22 9M'FY23 YoY (%) Revenues were Rs 2,296 Crore vs. Rs 1,917 Crore in 9M'FY22 Total Revenue 1,917 2,296 20% EBITDA was at Rs 433 Crore vs. Rs 321 Crore in 9M’FY22 with a a) Radiopharma 1,557 1,863 20% margin of 18.9% vs. 16
Slide 15: CDMO Sterile Injectables Segment Highlights – 9M'FY23
CDMO Sterile Injectables Segment Highlights – 9M'FY23 Particulars1 9M'FY22 9M'FY23 YoY (%) • CDMO Sterile Injectables’ revenue at Rs 833 Crore vs. Rs 1,046 Revenue 1,046 833 (20%) Crore in 9M'FY22. EBITDA 535 259 (51%) • Revenue and profitability normalised vs. 9M’FY22 as business Reported EBITDA Ma
Slide 16: Generics Segment Highlights – 9M'FY23
Generics Segment Highlights – 9M‘FY23 Particulars1 9M'FY22 9M'FY23 YoY (%) Generics revenue at Rs 563 Crore vs. Rs 936 Crore in 9M'FY22 with Revenue 936 563 (40%) benefits from Remdesivir sales of Rs 259 Crore. Reported EBITDA (32) (191) Reported EBITDA Margin (3.4%) (34.0%) Reported EBITDA was
Slide 17: CRDMO Segment Highlights – 9M'FY23
CRDMO Segment Highlights – 9M'FY23 Particulars1 9M'FY22 9M'FY23 YoY (%) Revenue at Rs 891 Crore vs. Rs 687 Crore in 9M'FY22 Total Revenue 687 891 30% a) Drug Discovery Services 315 391 24% EBITDA at Rs 153 Crore vs. Rs 157 Crore in 9M’FY22 with a margin of b) CDMO - API 372 500 35% 17.2% vs. 22.
Slide 18: Debt Profile
Debt Profile Particulars 31-03-22 30-06-22 30-09-22 31-12-22 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) (Rs. Crs) Long Term 2,874 2,986 3,068 3,113 Short Term 64 109 186 195 Total 2,938 3,095 3,254 3,308 Cash & Equivalent 984 1,027 846 647 Net Debt (On a Constant Currency Basis) 1,954 1,951 2,204 2,40
Slide 19: Key Business Priorities
Key Business Priorities Radiopharmaceuticals Continued ramping up of Ruby-Fill installations New Product Development and Filings (2 New Products in FY-24) Radiopharma Timely execution of MIBG roadmap to enable FY-25 launch Radiopharmacies Focus on launch of new products to gain significant m
Slide 20: Business outlook
Business outlook Speciality Pharmceuticals: In Radiopharma, we continue to build a long term pipeline of diagnostic and therapeutic radiopharmaceuticals and are executing a turnaround plan of Radiopharmacies, which is showing encouraging results. I131 MIBG clinical trials underway with launch expe
Slide 21: Appendix
Appendix 20
Slide 22: Income Statement – Q3 & 9M’FY23
Income Statement – Q3 & 9M’FY23 Particulars1 Q3'FY22 Q2 FY23 Q3'FY23 QoQ (%) YoY (%) 9M'FY22 9M'FY23 YoY (%) Revenue from Operations Specialty Pharmaceuticals 635 814 760 (7%) 20% 1,917 2,296 20% CDMO Sterile Injectables 265 299 272 (9%) 3% 1,046 833 (20%) Generics 171 161 223 38% 30% 936 563 (40%)
Slide 23: For more information visit us at www.jubilantpharmova.com
For more information For Investors: Siddharth Rangnekar Vineet V Mayer CDR India Ph: +91 120 436 1103 Ph: +91 +91 9769919966 E-mail: Vineet.mayer@jubl.com E-mail: siddharth@cdr-india.com For Media: Clayton Dsouza Madison Public Relations Sudhakar Safaya E-mail: clayton.dsouza@madisonpr.in Ph: +91 12